Jarl Ulf Jungnelius M.D. elected as executive director of the Biovica board of directors at annual shareholders meeting.

At the annual shareholders meeting on the 14th of October, Jarl Ulf Jungnelius was elected as Executive Director of the Biovica Board of Directors.   Ulf is a Board Certified Oncologist trained at the Karolinska University Institute/Hospital in Stockholm, Sweden and most recently held the position of Vice President CR&D Oncology at Celgene Inc. He [...]

2014-10-23T11:30:08+00:00 October 23rd, 2014 11:30|Regulatory|

Biovica enters research collaboration with Dana-Farber Cancer Institute

Biovica, a biotech company focused on improving cancer diagnostics and providing assays for better prediction of outcome and monitoring of cancer therapies, has entered into a research collaboration with the Dana-Farber Cancer Institute, Boston, MA. Biovica’s DiviTum™ technology that measures cell proliferation rate with high sensitivity & precision will be used in a clinical trial [...]

2014-10-17T09:40:32+00:00 October 17th, 2014 09:40|Regulatory|

Biovica receives EU funding for DiviTum™

The European Commission has selected Biovicas project “Clinical validation of the DiviTum™ assay in key European markets” to be funded through the Research and Innovation Framework Program Horizon 2020.   A total of 2 666 proposals were submitted to the first SME (Small Medium Enterprises) Instrument Calls within the European Commission´s R&D Program Horizon 2020. [...]

2014-10-08T11:45:19+00:00 October 8th, 2014 11:45|News|